Mallinckrodt Plc (MNKT): Hit that too

Play Episode

7min

Proactive - Interviews for investors

BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Proactive - Interviews for investors

Wedgemount Resources updates field activities at Huggy Assets, reactivates five wells

Wedgemount Resources CEO Mark Vanry joined Steve Darling from Proactive to provide an update to Proactive on the company's field activities at its recently acquired Huggy Assets. After weather-related delays, Wedgemount has full operations going, including pumping, surface facility optimization, maintenance, chemical treatments, and well workovers. The company's primary focus remains on the Echo and Novice operational areas, where five additional wells have been brought back online. These wells had been inactive for a significant period before Wedgemount's acquisition. Historical initial production (IP) rates for these wells ranged from 15 to 65 barrels of oil equivalent per day (boepd). Vanry noted that previous successful chemical stimulations on Wedgemount’s Willowbend leases resulted in improved well performance. The company expects similar or better results from workovers and chemical treatments at Huggy, potentially exceeding the original IP rates. Looking ahead, Wedgemount has over 100 additional wells that have yet to undergo chemical stimulation, presenting significant production upside over the next two years. #proactiveinvestors #westmountreosurcescorp #cse #wdgy #otcqb #wdgrf #OilProduction #TexasEnergy #EnergyInvesting #OilandGas #MarkVanry #ProactiveInvestors #EnergyStocks #Investing #OilExploration

Proactive - Interviews for investors

New Era Helium shifts focus to AI power needs with integrated energy strategy

New Era Helium CEO Will Gray joined Steve Darling from Proactive to outline the company’s strategic shift toward maximizing the value of its helium and natural gas assets in the Permian Basin to support the rapidly growing AI-driven economy. The company is positioning itself as a key player in behind-the-meter power generation, leveraging its resources to fuel high-performance computing and AI data centers. The company confirmed it remains on track to meet key production milestones while exploring an integrated energy strategy. Since 95% of the world’s helium is found in association with natural gas, the company sees a unique opportunity to directly contribute to the AI industry’s expanding power needs. Rather than selling natural gas as a commodity, New Era plans to utilize its Pecos Slope Gas Field to generate up to 70 megawatts (MW) of electricity for at least 20 years, supporting the rising demand for AI computing power. As part of this transition, the company’s joint venture, Texas Critical Data Centers, has signed a non-binding letter of intent to acquire land in Texas for a planned 250MW net-zero AI and high-performance computing center. This move aligns with increasing domestic demand for helium in semiconductor manufacturing and AI applications, further accelerated by the CHIPS and Science Act. New Era Helium anticipates providing a formal update on its Pecos Slope processing plant soon, signaling further progress in its energy-focused strategy. #proactiveinvestors #neweraheliuminc #nasdaq #nehc #oil #gas #perimianbasin #HeliumProduction #DataCenters #CarbonCapture #AI #Semiconductors #EnergyInnovation #NaturalGas #TechGrowth #SustainableEnergy

Followers	189
Posts	15063
Boards Moderated	0
Alias Born	08/26/2010

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free